Prostate Cancer

Findings from a preplanned analysis of the phase 4 CARD study demonstrated superior patient-reported outcomes with cabazitaxel in men with castration-resistant prostate cancer who received prior docetaxel and androgen receptor targeted therapy versus alternative AR-targeted treatment options.

Huma Q. Rana, MD, MPH, discusses the use of age at diagnosis to guide the utility of genetic testing in men with prostate cancer.

Arnulf Stenzl, MD, discusses the safety profile of enzalutamide in combination with androgen deprivation therapy in metastatic hormone-sensitive prostate cancer.

Neal D. Shore, MD, FACS, discusses the pivotal HERO trial, the promising safety data observed with relugolix, and the next steps for the agent in advanced prostate cancer.

Oliver Sartor, MD, discusses the significance of the REASSURE trial in patients with metastatic castration-resistant prostate cancer.

During a recent OncLive Peer Exchange, a panel of experts in advanced prostate cancer provided their insights on how best to employ 6 therapies that are enabling men with mCRPC to live longer.

Michael J. Morris, MD, discusses the ​design of the phase 3 CONDOR trial in men with biochemically recurrent prostate cancer.

Aaron E. Katz, MD, FACS, discusses redefining risk stratification for men with prostate cancer.

Interim data from a phase 2 study indicate that neoadjuvant hormone therapy may reduce tumor volume in men with high-risk prostate cancer planning to undergo radical prostatectomy.

Thomas A. Hope, MD, discusses the positive findings from a phase 3 imaging study, which utilized 68Ga-PSMA-11 PET in the detection of pelvic nodal metastasis in men with intermediate- or high-risk prostate cancer.

Neal D. Shore, discusses the potential utility of relugolix in patients with advanced prostate cancer.

Thomas Hope, MD, discusses the clinical impact of using 68Ga-PSMA-11 PET to detect pelvic nodal metastasis in men with intermediate- or high-risk prostate cancer.

Liquid biopsy with circulating tumor DNA could help alleviate some of the challenges of tissue biopsy in prostate cancer, and in doing so, lead to a better precision medicine model in the field.